[memb_sync_contact] [memb_has_any_tag tagid=369] [/memb_has_any_tag] [memb_has_any_tag tagid=475] [/memb_has_any_tag] [memb_has_any_tag tagid=477] [/memb_has_any_tag] [memb_has_any_tag tagid=479] [/memb_has_any_tag] [memb_has_any_tag tagid=481] [/memb_has_any_tag] [memb_has_any_tag tagid=483] [/memb_has_any_tag] [memb_has_any_tag tagid=485] [/memb_has_any_tag] [memb_has_any_tag tagid=487] [/memb_has_any_tag] [memb_has_any_tag tagid=489] [/memb_has_any_tag]

The purpose of this communication is to announce the influenza strains for the 2016-2017 influenza season. On March 4, 2016, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted overwhelmingly to recommend the influenza strains proposed by the World Health Organization (WHO) for the northern hemisphere influenza vaccine for the 2016-2017 influenza season. The selection results in 2 strains being changed for trivalent vaccines and 1 strain for quadrivalent vaccines for the 2016-2017 influenza season. Below is the list of strains that will be used in the US 2016-2017 vaccines: Trivalent Vaccines:  A/California/7/2009(H1N1)pdm09-like virus;  A/Hong Kong/4801/2014(H3N2)-like virus;  B/Brisbane/60/2008-like virus. Quadrivalent Vaccines:  In addition to the 3 strains mentioned above, B/Phuket/3073/2013-like virus. The influenza vaccine viruses selected by WHO for the 2016-2017 northern hemisphere influenza season are the same as those used for the 2016-2017 southern hemisphere for which Sanofi Pasteur produces and supplies Fluzone vaccine. Sanofi Pasteur has been producing 2 of the strains selected for the 2016-2017 influenza season since early January 2016.